[go: up one dir, main page]

DK3299368T3 - Hidtil ukendte aminopyrimidinderivater - Google Patents

Hidtil ukendte aminopyrimidinderivater Download PDF

Info

Publication number
DK3299368T3
DK3299368T3 DK17191467.4T DK17191467T DK3299368T3 DK 3299368 T3 DK3299368 T3 DK 3299368T3 DK 17191467 T DK17191467 T DK 17191467T DK 3299368 T3 DK3299368 T3 DK 3299368T3
Authority
DK
Denmark
Prior art keywords
hitherto unknown
aminopyrimidine derivatives
aminopyrimidine
derivatives
hitherto
Prior art date
Application number
DK17191467.4T
Other languages
English (en)
Inventor
Daniela Angst
Anna Vulpetti
François Gessier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3299368T3 publication Critical patent/DK3299368T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK17191467.4T 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater DK3299368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP14821285.5A EP3074386B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
DK3299368T3 true DK3299368T3 (da) 2020-05-25

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
DK20158961.1T DK3689865T3 (en) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
DK17191467.4T DK3299368T3 (da) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater
DK14821285.5T DK3074386T3 (da) 2013-11-29 2014-11-28 Nye aminopyrimidinderivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20158961.1T DK3689865T3 (en) 2013-11-29 2014-11-28 Hidtil ukendte aminopyrimidinderivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14821285.5T DK3074386T3 (da) 2013-11-29 2014-11-28 Nye aminopyrimidinderivater

Country Status (42)

Country Link
US (6) US9512084B2 (da)
EP (5) EP4606377A3 (da)
JP (2) JP6342495B2 (da)
KR (2) KR102380539B1 (da)
CN (2) CN105683181B (da)
AP (1) AP2016009158A0 (da)
AR (1) AR098549A1 (da)
AU (1) AU2014356069B2 (da)
BR (1) BR112016010397B1 (da)
CA (1) CA2926908C (da)
CL (1) CL2016001055A1 (da)
CR (1) CR20160244A (da)
CU (1) CU24384B1 (da)
CY (3) CY1119705T1 (da)
DK (3) DK3689865T3 (da)
EA (1) EA031218B1 (da)
EC (1) ECSP16054826A (da)
ES (4) ES2947770T3 (da)
FI (1) FI3689865T3 (da)
HR (3) HRP20171999T1 (da)
HU (3) HUE037588T2 (da)
IL (1) IL244943B (da)
JO (1) JO3314B1 (da)
LT (3) LT3074386T (da)
MA (1) MA39055B1 (da)
MX (1) MX367911B (da)
MY (2) MY191381A (da)
NO (1) NO3074386T3 (da)
NZ (1) NZ718835A (da)
PE (1) PE20160869A1 (da)
PH (1) PH12016500791A1 (da)
PL (3) PL3299368T3 (da)
PT (3) PT3689865T (da)
RS (3) RS56657B1 (da)
SI (3) SI3689865T1 (da)
SV (1) SV2016005206A (da)
TN (1) TN2016000128A1 (da)
TW (1) TWI652261B (da)
UA (1) UA117256C2 (da)
UY (1) UY35858A (da)
WO (1) WO2015079417A1 (da)
ZA (1) ZA201602275B (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3129470B1 (en) 2014-04-07 2021-04-07 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
RU2743657C2 (ru) 2014-10-08 2021-02-20 Новартис Аг Биомаркеры, прогнозирующие способность к терапевтическому ответу на терапию химерным рецептором антигена, и их применение
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
ES2876974T3 (es) * 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
JP7467117B2 (ja) 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3067602A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
AR113796A1 (es) * 2017-11-06 2020-06-10 Lilly Co Eli Compuestos inhibidores de tirosina cinasa de bruton (btk)
WO2019109053A1 (en) 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
KR20200110745A (ko) 2017-12-15 2020-09-25 주노 쎄러퓨티크스 인코퍼레이티드 항 - ｃｃｔ5 결합 분자 및 이의 사용 방법
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019241426A1 (en) 2018-06-13 2019-12-19 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CR20210045A (es) 2018-07-25 2021-06-18 Novartis Ag Inhibidores de inflamasoma nlrp3
CN120904205A (zh) 2018-08-29 2025-11-07 安塞塔制药公司 制备阿卡拉布替尼的方法
WO2020092848A2 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
BR112021007626A2 (pt) 2018-11-01 2021-10-13 Juno Therapeutics, Inc. Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
CA3120118A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
CN113710256A (zh) 2018-11-30 2021-11-26 朱诺治疗学股份有限公司 使用过继细胞疗法的治疗方法
MA54863A (fr) 2019-01-29 2021-12-08 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1)
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
JP7644027B2 (ja) 2019-05-23 2025-03-11 ノバルティス アーゲー Ｂｔｋ阻害剤の結晶形態
SI3972603T1 (sl) * 2019-05-23 2025-02-28 Novartis Ag Postopki zdravljenja sjogrenovega sindroma z uporabo zaviralca brutonove tirozin kinaze
ES3039974T3 (en) * 2019-05-23 2025-10-28 Novartis Ag A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
US20230121818A1 (en) * 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
EP4132542A2 (en) 2020-04-10 2023-02-15 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
AR123241A1 (es) 2020-08-14 2022-11-09 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
JP7443543B2 (ja) * 2021-01-26 2024-03-05 ノバルティス アーゲー 医薬組成物
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
WO2023031840A1 (en) 2021-09-03 2023-03-09 Novartis Ag Lou064 for treating multiple sclerosis
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR20250029137A (ko) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
US20240041929A1 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
AU2023351959A1 (en) 2022-09-30 2025-02-27 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
WO2025061148A1 (zh) * 2023-09-22 2025-03-27 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
NZ525656A (en) 2000-11-07 2004-12-24 Novartis Ag Indolylmaleimide derivatives as protein kinase C inhibitors
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP2322202A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune diseases
RU2005121672A (ru) 2002-12-09 2005-11-20 Зе Бод оф Риджентс оф зи Юнивесити оф Тексэс Систим (US) Способ ингибирования в условиях in vitro функции и/или пролиферации клетки, экспрессирующей тирозинкиназу janus 3 (jak3) (варианты), способ тестирования соединений in vitro в качестве перспективных терапевтических иммунодепрессантов и идентификации in vitro нового иммунодепрессивного лекарственного средства (варианты), стериозомер и фармацевтическая композиция на его основе, применение вышеуказанных объектов в качестве средства подавления нежелательной функции клетки у млекопитающего
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
CL2004001120A1 (es) 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
TW200716551A (en) 2005-03-10 2007-05-01 Cgi Pharmaceuticals Inc Certain substituted amides, method of making, and method of use thereof
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EP2068849A2 (en) 2006-09-11 2009-06-17 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
CA2680589A1 (en) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
WO2009137596A1 (en) 2008-05-06 2009-11-12 Cgi Pharmaceuticals, Inc. Substituted amides, method of making, and use as btk inhibitors
KR101523451B1 (ko) 2008-07-02 2015-05-27 에프. 호프만-라 로슈 아게 키나아제 억제제로서의 신규 페닐피라지논
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
AU2011219764A1 (en) * 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
EP2694486B1 (en) 2011-04-01 2018-01-10 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
PL2710007T3 (pl) 2011-05-17 2020-06-01 The Regents Of The University Of California Inhibitory kinazy
RS63418B1 (sr) 2011-06-10 2022-08-31 Merck Patent Gmbh Kompozicije i metode za proizvodnju jedinjenja pirimidina i piridina sa btk inhibitorskom aktivnošću
US20130178483A1 (en) 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
MX2014000338A (es) 2011-07-08 2014-05-01 Novartis Ag Derivados de pirrolo-pirimidina novedoso.
US9273317B2 (en) 2011-08-09 2016-03-01 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of MYC-driven tumor cells
CA3110966A1 (en) 2011-10-19 2013-04-25 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk)
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
BR112014013582A8 (pt) 2011-12-09 2017-06-13 Hoffmann La Roche inibidores de quinase de tirosina de bruton
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
CA2869954C (en) 2012-04-20 2023-01-03 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20140045813A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
CA2887435A1 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
PT3074386T (pt) 2017-11-15
LT3299368T (lt) 2020-05-25
HRP20171999T1 (hr) 2018-02-09
JP6342495B2 (ja) 2018-06-13
EA031218B1 (ru) 2018-12-28
IL244943B (en) 2020-04-30
HUE062248T2 (hu) 2023-10-28
AP2016009158A0 (en) 2016-04-30
SI3299368T1 (sl) 2020-07-31
PL3299368T3 (pl) 2020-08-10
KR20160088877A (ko) 2016-07-26
US9512084B2 (en) 2016-12-06
RS60251B1 (sr) 2020-06-30
CN110172056B (zh) 2022-04-19
EP3689865B1 (en) 2023-03-29
WO2015079417A1 (en) 2015-06-04
PH12016500791B1 (en) 2016-06-13
CY1126056T1 (el) 2023-11-15
SI3689865T1 (sl) 2023-07-31
HRP20200775T1 (hr) 2020-07-24
KR102421388B1 (ko) 2022-07-18
CU20160078A7 (es) 2016-09-30
LT3689865T (lt) 2023-07-10
CL2016001055A1 (es) 2016-10-28
DK3074386T3 (da) 2018-01-22
JP6667573B2 (ja) 2020-03-18
UA117256C2 (uk) 2018-07-10
JP2016538313A (ja) 2016-12-08
EP3299368B1 (en) 2020-02-26
CA2926908A1 (en) 2015-06-04
TN2016000128A1 (en) 2017-10-06
EP4219478A1 (en) 2023-08-02
HK1223368A1 (en) 2017-07-28
US20230312483A1 (en) 2023-10-05
CY1119705T1 (el) 2018-06-27
PH12016500791A1 (en) 2016-06-13
FI3689865T3 (fi) 2023-06-12
HUE049794T2 (hu) 2020-10-28
SI3074386T1 (en) 2018-02-28
PT3689865T (pt) 2023-06-16
EP4219478B1 (en) 2025-06-11
SV2016005206A (es) 2016-11-21
BR112016010397A8 (pt) 2020-04-22
TWI652261B (zh) 2019-03-01
DK3689865T3 (en) 2023-06-19
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
MY179059A (en) 2020-10-26
NZ718835A (en) 2021-12-24
CN110172056A (zh) 2019-08-27
RS56657B1 (sr) 2018-03-30
CN105683181B (zh) 2019-04-23
US20200010426A1 (en) 2020-01-09
ES2791525T3 (es) 2020-11-04
CY1122924T1 (el) 2021-10-29
EP4606377A2 (en) 2025-08-27
TW201609666A (zh) 2016-03-16
AU2014356069B2 (en) 2017-06-15
US20160235746A1 (en) 2016-08-18
PL3074386T3 (pl) 2018-03-30
EP4606377A3 (en) 2025-11-26
US10457647B2 (en) 2019-10-29
EP3074386B1 (en) 2017-10-11
EA201691125A1 (ru) 2016-09-30
PT3299368T (pt) 2020-05-28
ES2947770T3 (es) 2023-08-18
US20150152068A1 (en) 2015-06-04
EP3074386A1 (en) 2016-10-05
MA39055B1 (fr) 2018-10-31
HRP20230585T1 (hr) 2023-09-01
RS64275B1 (sr) 2023-07-31
IL244943A0 (en) 2016-05-31
JP2018141005A (ja) 2018-09-13
US20220041561A1 (en) 2022-02-10
ES2655527T3 (es) 2018-02-20
NO3074386T3 (da) 2018-03-10
AR098549A1 (es) 2016-06-01
CU24384B1 (es) 2019-03-04
ZA201602275B (en) 2017-08-30
PE20160869A1 (es) 2016-09-08
US11180460B2 (en) 2021-11-23
US20180251432A1 (en) 2018-09-06
CA2926908C (en) 2021-10-26
AU2014356069A1 (en) 2016-05-05
KR20220044370A (ko) 2022-04-07
PL3689865T3 (pl) 2023-07-31
CR20160244A (es) 2016-07-29
HK1252317A1 (en) 2019-05-24
MX2016006908A (es) 2016-08-17
MY191381A (en) 2022-06-22
ECSP16054826A (es) 2017-10-31
BR112016010397B1 (pt) 2023-04-11
HUE037588T2 (hu) 2018-09-28
KR102380539B1 (ko) 2022-03-29
LT3074386T (lt) 2017-12-27
CN105683181A (zh) 2016-06-15
US11673868B2 (en) 2023-06-13
ES3040769T3 (en) 2025-11-04
UY35858A (es) 2015-06-30
EP3299368A1 (en) 2018-03-28
MX367911B (es) 2019-09-11
MA39055A1 (fr) 2018-02-28

Similar Documents

Publication Publication Date Title
DK3299368T3 (da) Hidtil ukendte aminopyrimidinderivater
BR112016008141A2 (pt) Artigo
HUE037662T2 (hu) SYK inhibitorok
DK3613453T3 (da) Fordamper
EP2990093A4 (en) Dehumidifying device
EP2979854A4 (en) ITEMS
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
HRP20171890T1 (hr) Supstituirani imidazopiridazini
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
PL2945641T3 (pl) Cykloalkinowe pochodne sacharydów
DK2952513T3 (da) Azolbenzenderivat
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2969096A4 (en) Bottle pressurization delivery system
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
DK3087076T3 (da) Imidazopyrazinonderivater
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
EP3064843A4 (en) Dehumidifier